Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Medtronic
AstraZeneca
McKesson
McKinsey
Johnson and Johnson
Mallinckrodt

Last Updated: December 9, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for BGB-290

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

What is the drug development status for BGB-290?

BGB-290 is an investigational drug.

There have been 60 clinical trials for BGB-290. The most recent clinical trial was a Phase 1 trial, which was initiated on April 25th 2018.

The most common disease conditions in clinical trials are Lymphoma, Carcinoma, and Lung Neoplasms. The leading clinical trial sponsors are BeiGene, BeiGene USA, Inc., and Celgene.

There are three US patents protecting this investigational drug and thirty-four international patents.

Recent Clinical Trials for BGB-290
TitleSponsorPhase
Long-term Extension Study of Zanubrutinib (BGB-3111) in Patients With B-cell MalignanciesBeiGenePhase 3
A Study of Zanubrutinib (BGB-3111) in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Intolerant of Prior Treatment With IbrutinibBeiGenePhase 2
Study of BGB-A1217 in Combination With Tislelizumab in Advanced Solid TumorsBeiGenePhase 1

See all BGB-290 clinical trials

Clinical Trial Summary for BGB-290

Top disease conditions for BGB-290
Top clinical trial sponsors for BGB-290

See all BGB-290 clinical trials

US Patents for BGB-290

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
BGB-290   Start Trial Fused tetra or penta-cyclic dihydrodiazepinocarbazolones as PARP inhibitors BEIGENE, LTD. (Grand Cayman, KY)   Start Trial
BGB-290   Start Trial Fused tetra or penta-cyclic dihydrodiazepinocarbazolones as PARP inhibitors BeiGene, Ltd. (Grand Cayman, KY)   Start Trial
BGB-290   Start Trial Fused tetra or penta-cyclic dihydrodiazepinocarbazolones as PARP inhibitors BeiGene, Ltd. (Grand Cayman, KY)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Medtronic
McKesson
McKinsey
Boehringer Ingelheim
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.